Abstracts tagged "giant cell arteritis"

Abstract Number: 0080 • ACR Convergence 2023
Pharmacological Inhibition of PRMT5 Demonstrates Broad Efficacy in Multiple Preclinical Models of Autoimmunity and Inflammation by Suppressing Th1, Th17 and TNF-Mediated Inflammatory Responses
Neha Bhagwat¹, Kumar Penmetsa², Matt Devalaraja³, Suzana Marusic⁴, Cornelia M. Weyand⁵, Shozo Ohtsuki⁶, Peggy Scherle¹ and Kris Vaddi¹, ¹Prelude Therapeutics, Inc, Wilmington, DE, ²Thermo Fisher Scientific, Philadelphia, PA, ³Nipuna Therapeutics, Waltham, MA, ⁴Hooke Laboratories LLC, Lawrence, MA, ⁵Mayo Clinic School of Medicine and Stanford University, Rochester, MN, ⁶Mayo Clinic College of Medicine and Science, Stanford University School of Medicine, Rochester, MN
Background/Purpose: Protein arginine methyltransferase 5 (PRMT5) is the major type II PRMT that catalyzes the formation of symmetrical dimethyl arginine (SDMA) on protein substrates and…
Abstract Number: 1538 • ACR Convergence 2023
Large Vessel Involvement in Antineutrophil Cytoplasmic Antibody- Associated Vasculitis: A Single Center Experience over Two Decades
Mahmut Kaymakci¹, Mohanad Elfishawi¹, Hannah Langenfeld², Andrew Hanson², Cynthia Crowson¹, Melanie Bois¹, Umar Ghaffar¹, Ulrich Specks¹, Matthew Koster¹ and Kenneth Warrington¹, ¹Mayo Clinic, Rochester, MN, ²Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN
Background/Purpose: Anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) is currently categorized under the small vessel vasculitides and includes granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA),…
Abstract Number: 2389 • ACR Convergence 2023
Calprotectin (S100A8/S100A9) and Serumamyloid A Are Not Superior to C Reactive Protein and Erythrocyte Sedimentation Rate in Monitoring Disease Activity in Giant Cell Arteritis – Treated with or Without Tocilizumab
Matthias Froehlich¹, Marc Schmalzing², Hannah Labinsky³, Jan Portegys³, Ottar Gadeholt⁴, Patrick-Pascal Strunz¹, Eva C. Schwaneck⁵, Marcus Dittrich⁶, Tobias Mueller⁷ and Michael Gernert³, ¹Rheumatology/Clinical Immunology, Department of Internal Medicine II, University of Würzburg, Würzburg, Germany, ²University Hospital, Rheumatology/Clinical Immunology, Department of Internal Medicine II, Würzburg, Germany, ³Medical Department II, Rheumatology, University Hospital Würzburg, Würzburg, Germany, ⁴Rheumatologische Schwerpunktpraxis Würzburg, Würzburg, Germany, ⁵MVZ Rheumatologie und Autoimmunmedizin Hamburg GmbH, Hamburg, Germany, ⁶Department of Bioinformatics, Biocenter, Am Hubland, D-97074 University of Würzburg, Germany ; Institute for Human Genetics, Biocenter, Am Hubland, D-97074 University of Würzburg, Würzburg, Germany, ⁷Department of Bioinformatics, Biocenter, Am Hubland, D-97074 University of Würzburg, Würzburg, Germany
Background/Purpose: Monitoring disease activity in giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) remains challenging as standard inflammation parameters, i.e., C-reactive protein (CRP) and erythrocyte…
Abstract Number: 2406 • ACR Convergence 2023
Risk of Large Vessel Complications in Patients with Giant Cell Arteritis, a Population-based Study
Mohanad Elfishawi¹, Mahmut Kaymakci¹, Sara Achenbach², Cynthia Crowson¹, Tanaz Kermani³, Cornelia M. Weyand⁴, Matthew Koster¹ and Kenneth Warrington¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, MN, Rochester, MN, ³University of California Los Angeles, Los Angeles, CA, ⁴Mayo Clinic School of Medicine and Stanford University, Rochester, MN
Background/Purpose: Large vessel (LV) complications are known to occur in patients with giant cell arteritis (GCA). The magnitude of risk compared to the general population…
Abstract Number: 2424 • ACR Convergence 2023
Exploring the Limit of Image Resolution for Human Expert Classification of Vascular Ultrasound Images in Giant Cell Arteritis and Healthy Subjects: The GCA-US-AI Project
Valentin Sebastian Schäfer¹, Stavros Chrysidis², Christian Dejaco³, Sara Monti⁴, Matthew Koster⁵, Pantelis Karakostas¹, Wolfgang Schmidt⁶, Eugenio De Miguel⁷, Christina Duftner⁸, Alojzija Hocevar⁹, Annamaria Iagnocco¹⁰, Marcin Milchert¹¹, Chetan Mukhtyar¹², Cristina Ponte¹³, Lene Terslev¹⁴, Tanaz Kermani¹⁵, Uffe Møller Døhn¹⁶, Berit Dalsgaard Nielsen¹⁷, Aaron Juche¹⁸, Luca Seitz¹⁹, Minna Kohler²⁰, Kresten Keller²¹, Rositsa Karalilova²², Thomas Daikeler²³, Sarah Mackie²⁴, Karina Torralba²⁵, Kornelis van der Geest²⁶, Dennis Boumans²⁷, Philipp Bosch²⁸, Alessandro Tomelleri²⁹, Markus Aschwanden³⁰, Peter Brossart¹, Charlotte Behning³¹ and Claus Juergen Bauer¹, ¹Clinic of Internal Medicine III, Department of Oncology, Hematology, Rheumatology and Clinical Immunology, University Hospital of Bonn, Bonn, Germany, ²Department of Rheumatology, Southwest Jutland Hospital Esbjerg, Esbjerg, Denmark, ³Department of Rheumatology, Medical University Graz, Graz, Austria; Department of Rheumatology, Hospital of Bruneck (ASAA-SABES), Teaching Hospital of the Paracelsius Medical University, Brunico, Italy, ⁴Division of Rheumatology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; Department of Internal Medicine and Therapeutics, Università di Pavia, Pavia, Italy, ⁵Mayo Clinic, Rochester, MN, ⁶Rheumatology, Immanuel Krankenhaus Berlin, Medical Centre for Rheumatology Berlin-Buch, Berlin, Germany, ⁷Hospital Universitario La Paz, Madrid, Spain, ⁸Department of Internal Medicine, Clinical Division of Internal Medicine II, Medical University Innsbruck, Innsbruck, Austria, ⁹Department of Rheumatology, Universitiy Medical Centre Ljubljana, Ljubljana, Slovenia, ¹⁰University of Turin, Roma, Italy, ¹¹Department of Internal Medicine, Rheumatology, Diabetology, Geriatrics and Clinical Immunology, Pomeranian Medical University in Szczecin, Szczecin, Poland, ¹²Vasculitis service, Rheumatology department, Norfolk and Norwich University Hospital, Norwich, United Kingdom, ¹³Department of Rheumatology, Centro Hospitalar Universitário Lisboa Norte, Centro Académico de Medicina de Lisboa, Lisbon, Portugal; Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Centro Académico de Medicina de Lisboa, Lisbon, Portugal, ¹⁴Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark, ¹⁵Rheumatology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, ¹⁶Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, ¹⁷Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark; Department of Medicine, The Regional Hospital in Horsens, Horsens, Denmark, ¹⁸Department of Rheumatology, Immanuel Hospital, Berlin, Germany, ¹⁹Rheumatology and Immunology, Inselspital University Hospital Bern, Bern, Switzerland, ²⁰Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²¹Department of Rheumatology, Aarhus University Hospital; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark, ²²Clinic of Rheumatology, Medical University Plovdiv, Plovdiv, Bulgaria, ²³Clinic for Rheumatology, University Hospital Basel, Basel, Switzerland, ²⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ²⁵Division of Rheumatology, Department of Medicine, Loma Linda University School of Medicine, Loma Linda, CA, ²⁶Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ²⁷Rheumatology and Clinical Immunology, Hospital Group Twente, Almelo, Netherlands, ²⁸Medical University of Graz, Graz, Austria, ²⁹Unit of Immunology, Rheumatology, Allergy and Rare Diseases, San Raffaele Scientific Institute, Milano, Italy, ³⁰Department of Angiology, University Hospital Basel, Basel, Switzerland, ³¹Institute of Medical Biometry, Informatics and Epidemiology, University Hospital of Bonn, Bonn, Germany
Background/Purpose: Giant cell arteritis (GCA) is the most common form of vasculitis in adults, necessitating prompt diagnosis to prevent severe complications. However, access to expert…
Abstract Number: 0695 • ACR Convergence 2023
Impact and Cardiovascular Outcomes of Large Vessel Vasculitis in Atrial Fibrillation Hospitalization: A Nationwide Inpatient Database Study
Sabahat Usmani¹, Yanint Raksadawan¹, Amro Taha¹, Harigopal Sandhyavenu¹, Jalpan Patel¹, Thatiana Schulze Goni¹, Hafiz Muhammad Waqar Younas¹ and Irisha Badu², ¹Weiss Memorial Hospital, Chicago, IL, ²Onslow Memorial Hospital, Jacksonville, FL
Background/Purpose: Atrial fibrillation is the most commonly treated cardiac arrhythmia, associated with significant morbidity and mortality. Recent research is suggestive that autoimmunity and inflammation might…
Abstract Number: 1565 • ACR Convergence 2023
Baseline Vascular Ultrasound of Polymyalgia Rheumatica Patients at Time of Diagnosis Predicts Clinical Outcomes at 3 Months
Sharon Cowley¹, Colm Kirby², Patricia Harkins³, Richard Conway⁴ and David Kane⁵, ¹Tallaght University Hospital, Dublin, Dublin, Ireland, ²Tallaght University Hospital, Dublin, Ireland, ³St James's Hospital, Dublin, Ireland, ⁴Trinity College Dublin, Dublin, Ireland, ⁵Tallaght University Hospital & Trinity College Dublin, Dublin, Ireland
Background/Purpose: It has been reported that up to a quarter of patients with polymyalgia rheumatica (PMR) have subclinical giant cell arteritis (GCA). It is currently…
Abstract Number: 2390 • ACR Convergence 2023
Characterization of Senescent Cells in Temporal Arteries of Patients with Giant Cell Arteritis Reveal an Inflammatory Phenotype and Strong Dependence from IL-6
Dimitrios Veroutis¹, Ourania D Argryropouou¹, Andreas Goules², Konstantinos Kambas³, Dimitris Anastasios Palamidas¹, Konstantinos Evangelou¹, Sophia Havaki¹, Aikaterini Polyzou¹, Evangelia Xingi³, Elli Karatza⁴, Kyriaki Boki⁵, alberto cavazza⁶, Christos Kittas¹, Dimitris Thanos⁷, caterina Ricordi⁶, chiara marvisi⁶, Francesco Muratore⁸, Elena Galli⁶, Stefania Croci⁶, Carlo Salvarani⁹, Vassilis G Gorgoulis¹ and Athanasios Tzioufas², ¹National and Kapodistrian University of Athens, Athens, Greece, ²Dept. of Pathophysiology, School of Medicine, University of Athens, Athens, Greece, ³Hellenic Pasteur Institute, Athens, Greece, ⁴Laikon General Hospital, Athens, Greece, ⁵Sismanoglion Hospital, Athens, Greece, ⁶Azienda Unità Sanitaria Locale-IRCCS Di Reggio Emilia, Reggio Emilia, Italy, ⁷Biomedical Research Foundation of the Academy of Athens, Athens, Greece, ⁸IRCCS di Reggio Emilia, Reggio Emilia, Italy, ⁹Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy
Background/Purpose: Age is the strongest risk factor of giant cell arteritis (GCA), implying a possible pathogenetic role of cellular senescence. So far, no studies have…
Abstract Number: 2407 • ACR Convergence 2023
Immuno-permissive Antigen-presenting Cells in Giant Cell Arteritis
Shozo Ohtsuki¹, Chenyao Wang², Ryu Watanabe³, Hui Zhang³, Mitsuhiro Akiyama³, Kenneth Warrington⁴, Gerald J. Berry³, Jorg Goronzy⁴ and Cornelia M. Weyand⁵, ¹Mayo Clinic College of Medicine and Science, Stanford University School of Medicine, Rochester, MN, ²Mayo Clinic College of Medicine and Science, Rochester, MN, ³Stanford University School of Medicine, Stanford, CA, ⁴Mayo Clinic, Rochester, MN, ⁵Mayo Clinic School of Medicine and Stanford University, Rochester, MN
Background/Purpose: Giant cell arteritis (GCA) is a medium and large vessel vasculitis with pathognomonic granulomatous infiltrates in the vessel wall. During the early stages of…
Abstract Number: 2557 • ACR Convergence 2023
Clinicopathologic Features of Patients with Giant Cell Arteritis and Thoracic Aorta Repair: A Single Center Experience over Two Decades
Mahmut Kaymakci¹, Nicholas Boire¹, Melanie Bois¹, Mohanad Elfishawi¹, Hannah Langenfeld², Andrew Hanson², Cynthia Crowson¹, Matthew Koster¹, Cornelia M. Weyand³ and Kenneth Warrington¹, ¹Mayo Clinic, Rochester, MN, ²Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, ³Mayo Clinic School of Medicine and Stanford University, Rochester, MN
Background/Purpose: Patients with giant cell arteritis (GCA) are at increased risk of thoracic aortic aneurysm and dissection. This late complication of the disease is presumed…
Abstract Number: 0696 • ACR Convergence 2023
Association of Large-vessel Vasculitis with Inflammatory Bowel Diseases: A European Case-control Study
Francois Maillet¹, Yann Nguyen², Olivier Espitia³, Laurent Perard⁴, Carlo Salvarani⁵, Etienne Rivière⁶, Cécile-Audrey Durel⁷, Philippe GUILPAIN⁸, Luc Mouthon⁹, Anna Kernder¹⁰, Javier Loricera¹¹, Pascal Cohen¹², Isabelle Melki¹³, Claire De Moreuil¹⁴, Nicolas Limal¹⁵, Arsène Mekinian¹⁶, Nathalie Costedoat-Chalumeau¹⁷, Nathalie Morel¹², Jonathan Boutemy¹⁸, Loic Raffray¹⁹, Jean-Sébastien Allain²⁰, Valerie Devauchelle²¹, Isabelle Kone-Paut²², Marc Fabre²³, Marie Durel²⁴, Antoine Dossier²⁵, Sébastien Abad²⁶, Marcella Visentini²⁷, Adrien Bigot²⁸, Halil Yildiz²⁹, Olivier Fain³⁰, Maxime Samson³¹, Guillaume Gondran³², Vered Abitbol¹ and Benjamin Terrier³³, ¹Cochin Hospital, Paris, France, ²Department of Internal Medicine, Hôpital Beaujon, AP-HP, Clichy, France., Montmorency, France, ³CHU de Nantes, Nantes, France, ⁴CH Saint Hoseph Saint Luc, Lyon, France, ⁵Azienda USL -IRCCS di Reggio Emilia and Università di Modena e Reggio Emilia, Reggio Emilia, Italy, ⁶CHU Bordeaux, Bordeaux, France, ⁷CHU Lyon, Lyon, France, ⁸University of Montpellier, Montpellier, France, ⁹Hopital Cochin - Paris University, Paris, France, ¹⁰HHU Düsseldorf, Düsseldorf, Germany, ¹¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ¹²CHU Cochin, Paris, France, ¹³Hopital Robert Debré, Sérurier, France, ¹⁴CHU de Brest, Brest, France, ¹⁵AP-HP, Créteil, France, ¹⁶Department of Internal Medicine, Hôpital Saint-Antoine, AP-HP, Paris, France, ¹⁷Inserm DR Paris 5, Paris, France, ¹⁸CHU de Caen, Caen, France, ¹⁹CHU la Réunion, La Réunion, France, ²⁰CHU Rennes, Rennes, France, ²¹UBO, Brest, France, ²²Department of Pediatric Rheumatology, Reference Centre for Autoinflammatory Disorders CEREMAIA, Bicêtre Hospital, APHP, University of Paris Saclay, Paris, France, ²³CH Bourgoin-Jallieu, Bourgoin-Jallieu, France, ²⁴CH Metz, Metz, France, ²⁵AP-HP, Paris, France, ²⁶Avicenne Hospital, Bobigny, France, ²⁷Rome Hospital, Rome, France, ²⁸Tours Hospital, Tours, France, ²⁹Saint Luc Hospital, Bruxelles, Belgium, ³⁰Hopital SAINT ANTOINE APHP, Paris, France, ³¹Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France, ³²Limoges Hospital, Limoges, France, ³³Department of Internal Medicine, Hôpital Cochin, AP-HP, Paris, France
Background/Purpose: The association of large vessel vasculitis (LVV), whether Takayasu arteritis (TA) or giant cell arteritis (GCA), with inflammatory bowel disease (IBD) is a rare…
Abstract Number: 1645 • ACR Convergence 2023
Aortic Dilatation and PET/CT Vascular Activity at Diagnosis and 5 Years in an Inception Giant Cell Arteritis (GCA) Cohort
Anthony Sammel¹, Ivan Ho Shon², Daniel Moses¹, Fredericks Stacey¹, Gita Mathur¹, Claudia Hillenbrand³, Edward Hsiao⁴, Schembri Geoffrey⁴, Rodger Laurent⁴ and Eva Wegner², ¹Prince of Wales Hospital, Randwick, Australia, ²The Prince of Wales Hospital, Sydney, Australia, ³University of NSW, Randwick, Australia, ⁴Royal North Shore Hospital, St. Leonards, Australia
Background/Purpose: Aortic dilatation is typically a late complication of giant cell arteritis (GCA) but there are no tools to risk stratify patients at the time…
Abstract Number: 2391 • ACR Convergence 2023
Epidemiology and Predictors of Relapse in Giant Cell Arteritis: Results of the ARTESER Register
Javier Narvaez¹, Jesús Sanchez-Costa², Iñigo Hernández-Rodríguez³, Rafael Benito Melero-Gonzalez⁴, Eugenio De Miguel⁵, Irene Monjo⁶, Maite silva díaz⁷, LUCIA SILVA FERNANDEZ⁸, Joaquin Maria Belzunegui Otano⁹, Jesus Alejandro Valero-Jaimes¹⁰, Clara Moriano Morales¹¹, Ismael González¹², Julio Sanchez Martin¹³, Tomas Almorza Hidalgo¹⁴, Judit Lluch¹⁵, Eva Galindez-Agirregoikoa¹⁶, Itziar Calvo-Zorrilla¹⁶, Vicente Aldasoro¹⁷, Javier Mendizabal¹⁸, LYDIA ABASOLO¹⁹, PIA LOIS²⁰, Javier Loricera¹³, Noemi Garrido-Puñal²¹, ALBERTO MARIANO RUIZ ROMAN²², Santos Castañeda²³, Cristina Valero²³, Patricia Moya Albarado²⁴, Hector Corominas²⁵, Maria J. García-Villanueva²⁶, Carmen Larena²⁷, Paula V. Estrada-Alarcón²⁸, Vanessa Navarro²⁹, Carles Galisteo³⁰, Anne Riveros-Frutos³¹, Francisco Miguel Ortiz Sanjuan³², Selene Labrada-Arrabal³³, María Alcalde³⁴, Clara Molina Almela³⁵, Carlos Garcia Porrua³⁶, Maria García-González³⁷, Margarida Rocha³⁸, Antonio Juan Mas³⁹, Miguel A Gonzalez-Gay⁴⁰ and Ricardo Blanco⁴¹, ¹Hospital Universitario de Bellvitge, Barcelona, Spain, ²Unidad de Investigación de la Sociedad Española de Reumatología, Madrid, Spain, ³Hospital do Meixoeiro. Complejo Hospitalario Universitario de Vigo, Vigo, Spain, ⁴CHU Vigo, O Carballino, Spain, ⁵Hospital Universitario La Paz, Madrid, Spain, ⁶University Hospital La Paz, Madrid, Spain, ⁷Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC)., A Coruña, Spain, ⁸Complejo Hospitalario Universitario de la Coruña, Pontevedra, Spain, ⁹University Hospital Donostia, Donostia-San Sebasti, Spain, ¹⁰Hospital Bidasoa, Irún, Spain, ¹¹Rheumatology, Hospital Universitario de León, León, Spain, ¹²Hospital Universitario de León, León, Spain, ¹³Hospital Universitario Marqués de Valdecilla, Santander, Spain, ¹⁴Hospital Universitario 12 de Octubre, Madrid, Spain, ¹⁵Department of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ¹⁶Basurto University Hospital, Bilbao, Spain, ¹⁷Hospital Universitario de Navarra, Pamplona, Spain, ¹⁸Complejo Hospitalario de Navarra, Pamplona, Spain, ¹⁹Hospital Clínico San Carlos, Madrid, Spain, ²⁰Hospital Clinico San Carlos, Madrid, Spain, ²¹Hospital Universitario Virgen del Rocío, Sevilla, Spain, ²²Department of Rheumatology, Hospital Universitario Virgen del Rocío, Sevilla, Spain, ²³Hospital Universitario de la Princesa, Madrid, Spain, ²⁴Hospital Universitario de Sant Pau, Barcelona, Spain, ²⁵Hospital Universitario Sant Pau, Rheumatology, Barcelona, Spain, ²⁶Hospital Ramón y Cajal, Madrid, Spain, ²⁷Hospital Universitario Ramon y Cajal, Madrid, Spain, ²⁸Hospital de San Juan Despí Moisès Broggi, Barcelona, Spain, ²⁹Hospital de Sant Joan Despí – Moises Broggi, Barcelona, Spain, ³⁰Hospital Universitario Parc Taulí, Sabadell, Spain, ³¹Hospital Universitario Germans Trias i Pujol, Barcelona, Spain, ³²Hospital Universitario y Politecnico La Fe, Valencia, Spain, ³³Hospital del Mar, Barcelona, Spain, ³⁴Hospital Severo Ochoa, Madrid, Spain, ³⁵Hospital General de Valencia, Valencia, Spain, ³⁶Hospital Universitario Lucus Augusti, Lugo, Spain, ³⁷Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ³⁸Osakidetza, Bilbo, Spain, ³⁹Hospital Universitario Son Llàtzer, Mallorca, Spain, ⁴⁰IDIVAL and School of Medicine, UC, Santander; Department of Rheumatology, IIS-Fundación Jiménez Díaz, Madrid, Santander, Spain, ⁴¹Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: The relapse rate of treated patients with giant cell arteritis (GCA) varied widely in observational series and randomized controlled trials. This study aimed to…
Abstract Number: 2408 • ACR Convergence 2023
The Use of the Southend GCA Probability Score (GCAPS) in Assessing the Risk of Giant Cell Arteritis in Australian Ophthalmological and General Medical Hospital Cohorts
Eloise Norman¹, Clare Fraser², Mitchell Lawlor³ and Anthony Sammel⁴, ¹Prince of Wales Hospital, Randwick, Australia, ²Save Sight Institute, The University of Sydney, Sydney, Australia, ³Sydney and Sydney Eye Hospital, Sydney, Australia, ⁴The Prince of Wales Hospital, Sydney, Australia
Background/Purpose: The rate of positive temporal artery biopsies (TAB) in patients with suspected giant cell arteritis (GCA) varies widely, indicating the need for better pre-test…
Abstract Number: 2558 • ACR Convergence 2023
Aortic Aneurysms in a Multicenter Cohort of 196 Patients with Aortitis Related to Giant Cell Arteritis Treated with Tocilizumab
Fernando López¹, Javier Loricera², Adrián Martín-Gutiérrez³, Carmen Secada³, Santos Castañeda⁴, Clara Moriano Morales⁵, Javier Narvaez⁶, Vicente Aldasoro⁷, Olga Maiz⁸, Rafael Benito Melero-Gonzalez⁹, PALOMA VELA¹⁰, Susana Romero Yuste¹¹, Eugenio De Miguel¹², Eva Galindez-Agirregoikoa¹³, Jesús Carlos Fernández López¹⁴, Ivan Ferraz Amaro¹⁵, Julio Sánchez-Martín³, Jose L. Callejas¹⁶, Patricia Moya Albarado¹⁷ and Ricardo Blanco¹⁸, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, ⁴Hospital Universitario de la Princesa, Madrid, Spain, ⁵Rheumatology, Hospital Universitario de León, León, Spain, ⁶Hospital Universitario de Bellvitge, Barcelona, Spain, ⁷Hospital Universitario de Navarra, Pamplona, Spain, ⁸Hospital Universitario de Donostia. San Sebastián, Spain., Donosti, Spain, ⁹CHU Vigo, O Carballino, Spain, ¹⁰Rheumatology, Hospital General Universitario Alicante, Alicante, Spain, ¹¹Complexo Hospitalario Universitario, Pontevedra, Spain, ¹²Hospital Universitario La Paz, Madrid, Spain, ¹³Basurto University Hospital, Bilbao, Spain, ¹⁴Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC), A Coruña, Spain, ¹⁵Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ¹⁶Unit of Systemic Autoimmune Diseases, Hospital San Cecilio, Granada, Spain, ¹⁷Hospital Universitario de Sant Pau, Barcelona, Spain, ¹⁸Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Aortic aneurysms is a serious complication that can occur in patients with giant cell arteritis (GCA) (1-2). Tocilizumab (TCZ) is approved for GCA. Nevertheless,…

« Previous Page
1
…
6
7
8
9
10
…
32
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].